Dr. Constantine Alifrangis focused on the study of cancer
genomes and how it might be used to identify new treatments and individualize care for patients with mesothelioma. These approaches have identified specific genomic alterations in mesothelioma associated with unexpected drug sensitivities in mesothelioma. As for other
cancers, study of cancer genomes in mesothelioma has the potential to guide development of novel therapies for this disease.
Click here to hear and see more about this work.
